TXG - What's Going On With 10x Genomics Stock On Wednesday? | Benzinga
Wednesday, Illumina Inc (NASDAQ:ILMN) acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research for an undisclosed consideration.
Amid this M&A deal, 10x Genomics, Inc (NASDAQ:TXG) shares are trading lower.
William Blair writes that Fluent’s PIPseq single-cell technology does not require an instrument, and costs per cell is at least 50% less than 10x and is the cheapest on the market, citing a recent bioRxiv preprint.
William Blair highlights that cost reduction has become crucial in the increasingly crowded single-cell market. Bundled offerings will further strengthen Fluent’s competitive edge with low-cost positioning. While Illumina emphasizes its commitment to the NGS platform, ...